ebolaviru
caus
highli
fatal
panicgener
human
diseas
may
jump
bat
mammal
human
high
viral
load
bodi
fluid
allow
effici
transmiss
contact
lack
effect
antivir
vaccin
public
health
infrastructur
part
africa
make
difficult
health
worker
contain
outbreak
ebolaviru
known
caus
outbreak
sever
hemorrhag
fever
high
fatal
africa
sinc
howev
ebolaviru
spotlight
clinic
scientif
commun
mainli
affect
remot
villag
involv
hundr
peopl
outbreak
often
stop
spontan
larg
ebolaviru
outbreak
occur
west
africa
outbreak
first
report
guinea
march
although
epidemiolog
investig
suggest
first
fatal
case
occur
decemb
outbreak
spread
liberia
sierra
leon
nigeria
seneg
mali
africa
first
case
diagnos
outsid
africa
report
usa
septemb
octob
three
nurs
acquir
ebolaviru
local
unit
state
spain
gener
huge
media
attent
public
panic
west
africa
ebolaviru
outbreak
unpreced
mani
way
firstli
largest
ebolaviru
outbreak
record
histori
case
mortal
rate
secondli
outbreak
involv
major
citi
includ
conakri
guinea
freetown
sierra
leon
monrovia
liberia
lago
nigeria
involv
major
citi
increas
risk
rapid
local
dissemin
spread
neighbor
countri
transcontinent
spread
air
travel
therefor
present
major
health
threat
entir
world
review
basic
scienc
epidemiolog
clinic
aspect
ebolaviru
relev
control
current
outbreak
ebolaviru
togeth
marburgviru
cuevaviru
three
genera
belong
famili
filovirida
order
mononegaviral
four
speci
within
ebolaviru
genu
caus
fatal
human
diseas
includ
sudan
gabon
locat
central
east
africa
zair
sudan
ebolaviru
respons
outbreak
speci
associ
highest
casefat
rate
rang
respect
forest
ebolaviru
caus
ill
ethnologist
perform
necropsi
infect
chimpanze
cote
divoir
west
africa
bundibugyo
ebolaviru
associ
two
outbreak
sinc
rel
low
casefat
rate
reston
ebolaviru
caus
diseas
pig
fatal
monkey
definit
associ
human
diseas
although
asymptomat
infect
diagnos
serolog
test
identifi
person
contact
infect
monkey
pig
addit
clinic
appar
evd
outbreak
seroepidemiolog
studi
show
high
preval
seroposit
individu
suggest
asymptomat
mild
infect
occur
studi
test
blood
sampl
collect
individu
randomli
select
villag
gabon
sampl
found
ebolavirusspecif
antibodi
use
elisa
ebolavirusspecif
antibodi
also
found
individu
area
without
appar
evd
outbreak
exampl
ebolavirusspecif
antibodi
detect
use
indirect
immunofluoresc
slide
test
found
healthi
individu
rainforest
area
liberia
earli
though
serolog
test
result
confirm
neutral
antibodi
studi
highli
like
asymptomat
mildli
symptomat
infect
much
common
sever
symptomat
fatal
ill
current
west
africa
evd
outbreak
start
decemb
case
first
appear
meliand
villag
gu
eck
edou
guinea
tabl
index
patient
child
fever
black
stool
vomit
symptom
onset
decemb
die
day
later
diseas
spread
villag
gu
eck
edou
district
also
macenta
kissidoug
district
first
peak
occur
march
patient
diagnos
evd
liberia
second
peak
occur
may
june
coincid
first
report
case
sierra
leon
contact
trace
found
initi
case
sierra
leon
attend
funer
highli
respect
tradit
healer
treat
patient
evd
guinea
larg
increas
case
sinc
juli
first
case
nigeria
travel
liberia
caus
outbreak
involv
laboratoryconfirm
case
juli
septemb
seneg
mali
report
first
import
case
august
octob
respect
first
case
evd
diagnos
outsid
africa
confirm
septemb
patient
liberia
arriv
usa
septemb
develop
symptom
septemb
separ
evd
outbreak
also
caus
zair
ebolaviru
occur
drc
sinc
juli
octob
drc
outbreak
involv
case
death
togeth
epidemiolog
data
viral
genom
data
provid
import
inform
origin
transmiss
dynam
west
africa
ebolaviru
strain
phylogenet
analysi
use
whole
genom
sequenc
ebolaviru
strain
patient
reveal
west
africa
evd
outbreak
caus
zair
ebolaviru
lineag
close
relat
one
caus
evd
outbreak
drc
molecular
date
suggest
west
african
lineag
like
diverg
central
african
lineag
analysi
ebolaviru
strain
guinea
sierra
leon
show
highli
similar
agreement
find
contact
trace
fig
howev
two
distinct
lineag
ebolaviru
sierra
leon
estim
diverg
april
find
suggest
viru
mutat
either
guinea
sierra
leon
hand
ebolaviru
strain
caus
drc
evd
outbreak
juli
anoth
zair
strain
close
relat
drc
outbreak
zair
strain
confirm
separ
outbreak
largest
evd
outbreak
affect
less
peopl
howev
current
outbreak
alreadi
case
death
octob
studi
must
undertaken
understand
viral
environment
factor
contribut
unpreced
scale
outbreak
still
uncertain
stage
whether
viru
becom
transmiss
human
increas
environment
stabil
unclear
zair
ebolaviru
suddenli
appear
west
africa
human
case
ebolaviru
infect
west
africa
outbreak
occur
year
ago
epidemiolog
investig
suggest
first
patient
child
meliand
villag
gu
eck
edou
one
postul
spread
viru
fruit
bat
central
africa
requir
confirm
field
studi
human
acquir
infect
infect
anim
infect
person
index
patient
evd
outbreak
usual
person
work
forest
cave
mine
mani
index
patient
bushmeat
hunter
direct
contact
anim
natur
set
transmiss
anim
usual
involv
direct
contact
anim
handl
carcass
howev
human
acquir
infect
direct
persontoperson
transmiss
occur
via
direct
contact
bodi
fluid
mani
cluster
occur
peopl
attend
funer
infect
patient
caseecontrol
studi
show
household
contact
direct
physic
contact
ill
patient
cadav
exposur
bodi
fluid
risk
factor
acquir
infect
ebolaviru
transmit
directli
broken
skin
mucou
membran
blood
bodi
fluid
secret
infect
person
viru
could
detect
blood
urin
saliva
semin
fluid
breast
milk
tear
stool
skin
swab
vagina
rectum
conjunctiva
viru
shed
prolong
reversetranscriptas
polymeras
chain
reaction
rtpcr
remain
posit
blood
day
vagin
rectal
conjunctiv
swab
day
semin
fluid
day
live
viru
could
isol
patient
semin
fluid
day
symptom
onset
transmiss
environment
surfac
possibl
shown
live
ebolaviru
surviv
dri
glass
plastic
surfac
day
studi
shown
lower
temperatur
higher
absolut
humid
associ
evd
outbreak
anim
studi
show
rout
may
possibl
reston
ebolaviru
transmit
pig
cynomolgu
macaqu
without
direct
contact
suggest
ebolaviru
transmit
anim
reservoir
human
without
direct
contact
studi
rhesu
macaqu
show
ebolaviru
given
oral
caus
fatal
infect
aerosol
transmiss
macaqu
document
rout
transmiss
document
human
almost
case
current
outbreak
relat
persontoperson
transmiss
effect
reproduct
number
outbreak
estim
guinea
liberia
nigeria
sierra
leon
hospitalacquir
infect
common
evd
outbreak
index
case
transmit
viru
healthcar
worker
hospit
patient
least
gener
persontoperson
transmiss
current
outbreak
least
healthcar
worker
infect
least
death
addit
ebolaviru
also
transmit
indirectli
broken
skin
mucou
membran
come
contact
contamin
environ
item
soil
cloth
bed
linen
use
needl
unsteril
syring
associ
outbreak
zair
one
studi
viru
could
also
found
doctor
bloodstain
glove
bloodi
intraven
insert
site
found
patient
surround
environ
laboratoryacquir
infect
accident
punctur
handl
infect
materi
report
detail
analysi
confirm
probabl
ebolaviru
case
guinea
liberia
nigeria
sierra
leon
decemb
septemb
median
age
year
interquartil
rang
year
male
femal
ratio
incub
period
usual
day
short
day
long
day
current
outbreak
mean
incub
period
day
patient
symptom
onset
within
day
ebolaviru
found
sever
anim
includ
bat
primat
chimpanze
gorilla
rodent
rat
mice
shrew
duiker
cephalophu
speci
pig
although
ebolavirusspecif
antibodi
detect
serum
sampl
dog
ebolaviru
endem
area
report
isol
ebolaviru
detect
ebolaviru
nucleic
acid
dog
sampl
anim
ebolaviru
caus
epidem
fatal
diseas
estim
ebolaviru
outbreak
drc
reduct
chimpanze
gorilla
duiker
popul
respect
bat
propos
sourc
ebolaviru
bat
known
sourc
sever
human
virus
includ
sever
acut
respiratori
syndromerel
coronaviru
sarscov
hendra
viru
nipah
viru
menangl
viru
rabi
viru
lyssavirus
ebolaviru
first
report
found
fruit
bat
speci
hypsignathu
monstrosu
epomop
franqueti
myonycteri
torquata
captur
outbreak
gabon
drc
investig
outbreak
drc
found
affect
area
larg
palm
plantat
migratori
fruit
bat
settl
food
april
may
first
human
case
ate
freshli
kill
bat
bought
hunter
may
ebolaviru
limit
africa
serolog
studi
show
antibodi
zair
reston
ebolaviru
could
detect
fruit
bat
bangladesh
reston
ebolaviru
could
detect
fruit
bat
philippin
studi
china
show
bat
seroposit
ebolaviru
common
bat
speci
ebolaviru
identifi
china
includ
rousettu
leschenaultia
hipposidero
pomona
miniopteru
schreibersii
pipistrellu
pipistrellu
myoti
ricketti
novel
virus
also
identifi
reston
ebolaviru
found
domest
pig
philippin
china
antibodi
specif
ebolaviru
speci
found
ape
indonesia
like
filovirus
ebolaviru
filament
envelop
viru
negativesens
nonseg
singlestrand
genom
kb
measur
nm
diamet
nm
length
end
viral
genom
consist
noncod
region
follow
gene
nucleoprotein
noncod
region
end
gene
encod
one
protein
except
gp
gene
encod
three
glycoprotein
fulllength
gp
produc
rna
edit
two
read
frame
join
togeth
slippag
viral
polymeras
edit
site
gener
mrna
transcript
allow
readthrough
translat
gp
gp
contain
subunit
host
cell
receptor
bind
subunit
cellvirion
membran
fusion
solubl
gp
sgp
gener
unedit
transcript
much
abund
gp
third
protein
call
small
solubl
gp
ssgp
produc
via
rna
edit
gp
associ
membran
np
l
protein
bind
viral
genom
requir
viral
genom
replic
transcript
also
requir
assembl
nucleocapsid
viral
life
cycl
start
attach
cell
surfac
receptor
although
ebolaviru
bind
host
cell
surfac
dendrit
cell
dc
specif
nonintegrin
sign
dcsign
liver
lymph
node
sign
lsign
cell
immunoglobulin
mucin
domaincontain
current
unclear
cell
surfac
receptor
import
attach
viral
entri
occur
via
macropinocytosi
clathrinmedi
endocytosi
entri
viru
traffick
endosom
insid
endosom
sever
factor
requir
fusion
viral
endosom
membran
occur
includ
acidif
endosom
prime
trigger
gp
prime
gp
occur
bound
cleav
kda
cathepsin
l
kda
cathepsin
b
trigger
occur
kda
undergo
conform
chang
expos
fusion
loop
anoth
import
event
fusion
step
bind
endosom
membran
protein
niemannpick
cleav
viral
genom
replic
transcript
take
place
cytoplasm
requir
viral
polymeras
l
protein
np
requir
nucleocapsid
format
assembl
viral
transcript
also
regul
gp
modif
golgi
traffick
plasma
membran
associ
protein
viru
bud
releas
occur
requir
matrix
protein
addit
viral
life
cycl
viral
protein
also
involv
pathogenesi
infect
gp
caus
destruct
endotheli
cell
sever
line
evid
suggest
sgp
import
modul
host
inflammatori
respons
immun
defens
vitro
sgp
inhibit
neutral
activ
antigp
antibodi
sgp
also
subvert
antigp
immun
respons
induc
host
antibodi
compet
bind
site
antigp
antibodi
sgp
also
interact
neutrophil
although
receptor
interact
controversi
hand
sgp
may
limit
virul
viru
recombin
ebolaviru
without
sgp
less
cytotox
sgp
sgp
protect
endotheli
cell
tnfa
sgp
also
bind
import
find
requir
studi
also
inhibit
innat
immun
rigi
signal
interferon
ifn
ifnb
product
dendrit
cell
matur
import
inhibit
ifn
signal
current
unclear
whether
west
africa
ebolaviru
strain
possess
uniqu
characterist
favor
spread
among
human
popul
one
possibl
reason
higher
mutat
rate
shown
mutat
rate
current
outbreak
twice
high
previou
outbreak
decontamin
method
ebolaviru
includ
heat
inactiv
c
h
c
min
girradi
chemic
includ
formalin
quaternari
ammonium
ion
nanoemuls
disrupt
membran
case
ebolaviru
like
enter
bodi
via
break
skin
mucou
membran
infect
monocyt
macrophag
dendrit
cell
help
dissemin
viru
lymph
node
via
lymphat
liver
spleen
via
blood
notabl
ebolaviru
infect
lymphocyt
although
lymphocyt
deplet
occur
due
apoptosi
infect
monocyt
macrophag
dendrit
cell
move
lymph
node
spleen
viru
dissemin
organ
ebolaviru
also
infect
endotheli
cell
fibroblast
hepatocyt
adren
cortic
cell
epitheli
cell
sinc
patient
sever
diseas
higher
viral
load
blood
uncontrol
viral
replic
may
play
import
role
pathogenesi
sever
evd
macroscop
hemorrhag
lesion
skin
mucou
membran
viscer
organ
autopsi
microscop
examin
reveal
necrosi
mani
organ
includ
liver
spleen
kidney
gonad
liver
also
evid
apoptosi
microvesicular
steatosi
kupffer
cell
hyperplasia
councilman
bodi
apoptot
liver
cell
dislodg
adjac
hepatocyt
may
present
eosinophil
oval
filament
cytoplasm
inclus
may
present
aggreg
ebolaviru
np
examin
lung
show
hemorrhag
diffus
alveolar
damag
infect
adren
gland
document
human
adren
necrosi
may
one
possibl
pathogen
mechan
lead
hypotens
mark
coagulopathi
hallmark
evd
dissemin
intravascular
coagul
frequent
occur
believ
tissu
factor
secret
monocytesmacrophag
relat
coagulopathi
macaqu
level
protein
c
reduc
coagulopathi
protein
c
import
inflammatori
respons
studi
rhapctreat
rhesu
macaqu
better
outcom
higher
level
gene
transcript
regul
ccaat
enhancerbind
protein
alpha
tumor
protein
megakaryoblast
leukemia
myocardinlik
protein
although
viru
infect
endotheli
cell
vascular
lesion
seen
postmortem
tissu
therefor
sever
bleed
unlik
relat
direct
destruct
blood
vessel
ebolaviru
similar
caus
sever
sepsi
cytokinechemokin
dysregul
occur
patient
sever
diseas
fatal
case
high
level
one
studi
asymptomat
patient
elev
level
tnfa
plasma
howev
one
studi
gene
express
level
cytokin
peripher
blood
mononuclear
cell
infect
patient
differ
noninfect
patient
level
plasma
nitric
oxid
higher
fatal
nonfat
case
high
level
nitric
oxid
may
contribut
lymphocyt
apoptosi
tissu
vascular
damag
may
associ
hemodynam
instabl
seen
fatal
case
one
major
innat
defens
mechan
viral
infect
ifn
pathway
ifn
produc
cell
upon
viral
infect
induc
sever
protein
includ
ifninduc
transmembran
protein
ifitm
shown
type
ifn
lesser
extent
restrict
cell
entri
ebolaviru
mention
viral
protein
interfer
ifn
pathway
may
turn
dampen
prime
effect
adapt
immun
respons
thu
allow
viru
replic
high
titer
import
humor
cellmedi
immun
respons
illustr
studi
compar
surviv
fatal
case
ebolavirusspecif
igm
igg
detect
survivor
earli
cours
ill
posit
titer
detect
earli
day
symptom
onset
contrast
one
third
none
fatal
case
detect
igm
igg
respons
respect
activ
cytotox
cell
indic
upregul
fasl
perforin
mrna
express
observ
time
viral
clearanc
survivor
level
ifng
solubl
fa
solubl
fasl
low
recoveri
phase
suggest
regul
cytotox
cell
respons
recoveri
phase
fatal
case
level
ifng
solubl
fa
solubl
fasl
elev
increas
death
suggest
massiv
activ
cytotox
cell
natur
infect
neutral
antibodi
produc
patient
persist
serumneutr
activ
igg
immunoreact
least
year
infect
found
survivor
monoclon
antibodi
gp
shown
protect
nonhuman
primat
lethal
infect
postexposur
prophylaxi
treatment
level
antigp
igg
highli
correl
surviv
guinea
pig
cynomolgu
macaqu
vaccin
gp
express
adenoviru
vesicular
stomat
viru
vector
antibodi
also
critic
confer
protect
cynomolgu
macaqu
vaccin
recombin
vesicular
stomat
viru
express
gp
vaccin
studi
anim
provid
clue
contribut
cell
mediat
immun
confer
protect
mice
studi
show
viruslik
particl
induc
protect
immun
wild
type
mice
nkcell
deplet
mice
therefor
suggest
nk
cell
import
protect
immun
role
cell
controversi
one
studi
show
cell
requir
confer
protect
anoth
studi
show
requir
despit
high
casefat
rate
mani
individu
asymptomat
infect
evidenc
high
percentag
seroposit
individu
although
mani
factor
may
determin
whether
patient
develop
symptomat
diseas
host
genet
differ
like
play
import
role
infecti
diseas
mice
differ
genet
background
differ
suscept
ebolaviru
infect
possibl
relat
variat
tek
gene
respons
coagul
evd
typic
progress
rapidli
multisystem
involv
particular
coagulopathi
lead
sever
hemorrhag
earli
stage
ill
patient
usual
exhibit
acut
onset
nonspecif
flulik
symptom
includ
fever
chill
myalgia
headach
follow
gastrointestin
symptom
includ
abdomin
pain
nausea
vomit
diarrhea
respiratori
symptom
cough
sore
throat
may
also
occur
maculopapular
rash
typic
occur
day
symptom
onset
associ
erythema
desquam
hemorrhag
phenomenon
appear
includ
petechia
ecchymos
uncontrol
ooz
venipunctur
site
mucos
hemorrhag
howev
note
massiv
hemorrhag
occur
fewer
half
patient
seldom
caus
death
outbreak
unexplain
bleed
report
patient
hypovolemia
develop
rapidli
caus
sever
sepsi
complic
includ
dissemin
intravascular
coagulopathi
multiorgan
failur
occur
death
usual
occur
day
symptom
onset
survivor
usual
improv
day
neutral
antibodi
start
develop
convalesc
phase
myeliti
recurr
hepat
psychosi
uveiti
may
develop
pregnant
women
may
increas
risk
sever
ill
death
also
increas
risk
spontan
abort
pregnancyrel
hemorrhag
outbreak
drc
fetal
neonat
loss
occur
third
trimest
pregnanc
fact
first
case
evd
sierra
leon
pregnant
woman
miscarriag
blood
test
may
show
thrombocytopenia
leukopenia
hepat
dysfunct
elev
level
aspart
aminotransferas
alanin
aminotransferas
amylas
ddimer
hemolysi
sever
especi
acut
stage
blood
film
may
also
show
atyp
lymphocyt
renal
impair
usual
appear
end
first
week
fatal
case
higher
viral
load
blood
despit
fatal
diseas
infect
patient
individu
develop
symptom
evd
outbreak
gabon
asymptomat
individu
direct
exposur
infect
materi
identifi
eleven
patient
develop
specif
igm
igg
respons
ebolaviru
furthermor
rtpcr
ebolaviru
posit
peripher
blood
mononuclear
cell
sampl
seroposit
individu
positivestrand
rna
presenc
suggest
activ
replic
detect
individu
sinc
high
grade
viremia
occur
acut
period
prefer
diagnost
test
rtpcr
blood
rtpcr
target
np
perform
serum
plasma
whole
blood
oral
fluid
rnaemia
detect
day
symptom
onset
viral
load
log
copi
per
ml
viral
load
increas
rapidli
reach
log
day
symptom
onset
level
rnaemia
peak
day
symptom
onset
level
rnaemia
higher
fatal
case
survivor
antigencaptur
elisa
also
use
blood
sampl
less
sensit
rtpcr
rapid
immunochromatograph
assay
detect
ebolaviru
antigen
claim
provid
result
min
recent
announc
franc
atom
energi
commiss
viral
cultur
blood
use
vero
usual
posit
acut
stage
perform
except
biosafeti
level
facil
viral
particl
may
seen
serum
electron
microscop
use
confirm
first
case
current
outbreak
blood
sampl
oral
fluid
viru
also
detect
bodi
fluid
usual
use
diagnosi
serum
igm
use
convalesc
phase
use
acut
set
serum
igg
reliabl
one
studi
show
survivor
detect
igg
level
time
viral
antigen
longer
detect
sever
biomark
propos
associ
advers
outcom
addit
elev
cytokinechemokin
level
level
thrombomodulin
ferritin
also
elev
patient
poor
outcom
protein
produc
platelet
respons
repair
damag
endothelium
higher
survivor
current
cornerston
manag
patient
evd
support
care
although
taken
grant
develop
countri
support
measur
usual
lack
affect
area
poor
healthcar
infrastructur
aggress
volum
electrolyt
manag
oral
intraven
nutrit
medic
control
fever
gastrointestin
distress
medic
treat
pain
anxieti
agit
import
measur
coinfect
activ
sought
treat
appropri
current
licens
antivir
drug
treat
evd
outbreak
specif
therapi
use
human
success
evd
outbreak
male
investig
prick
transfer
homogen
liver
infect
guinea
pig
six
day
injuri
develop
fever
central
abdomin
pain
nausea
day
start
receiv
cours
human
ifn
million
unit
everi
h
administ
intramuscularli
human
ifn
prepar
stimul
peripher
lymphocyt
sendai
viru
vitro
day
injuri
receiv
ml
convalesc
sera
obtain
infect
peopl
zair
viral
load
reduc
guineapig
infect
unit
per
ml
guineapig
infect
unit
per
ml
day
injuri
receiv
infus
convalesc
sera
eventu
recov
subsequ
ebolaviru
outbreak
kikwit
patient
receiv
blood
donat
convalesc
patient
surviv
convalesc
plasma
ifnb
later
test
rhesu
macaqu
convalesc
plasma
found
improv
surviv
evd
outbreak
convalesc
plasma
given
sever
patient
efficaci
convalesc
plasma
remain
determin
addit
convalesc
plasma
ifnb
sever
experiment
treatment
shown
improv
surviv
nonhuman
primat
tabl
first
strategi
employ
antivir
effect
neutral
antibodi
either
direct
administr
antibodi
activ
immun
monoclon
antibodi
cocktail
target
differ
site
ebolaviru
shown
protect
primat
zmapp
cocktail
monoclon
antibodi
origin
contain
prepar
consist
human
humanmous
chimer
mab
zmab
consist
murin
mab
target
gp
shown
protect
rhesu
macaqu
lethal
challeng
given
day
post
infect
postexposur
vaccin
vesicular
stomat
virusbas
vaccin
elicit
antigp
antibodi
improv
surviv
rhesu
macaqu
given
min
post
infect
second
strategi
inhibit
activ
viru
protein
antisens
oligonucleotid
target
viral
l
protein
vp
protein
also
improv
surviv
infect
rhesu
macaqu
third
strategi
aim
amelior
deleteri
host
immun
respons
recombin
nematod
anticoagul
protein
recombin
human
activ
protein
c
could
allevi
coagulopathi
improv
surviv
anim
model
howev
clinic
efficaci
recombin
human
activ
protein
c
question
random
doubleblind
placebocontrol
studi
show
surviv
benefit
patient
septic
shock
among
experiment
treatment
monoclon
antibodi
cocktail
zmapp
small
interf
rna
tkmebola
use
patient
current
outbreak
antibodi
rnabas
therapi
might
limit
particular
speci
may
becom
ineffect
mutat
affect
relat
antigen
epitop
gene
target
efficaci
experiment
treatment
human
remain
determin
sever
drug
current
undergo
clinic
trial
antivir
activ
ebolaviru
one
promis
nucleotid
analog
brincidofovir
lipidconjug
prodrug
cidofovir
convert
intracellularli
cidofovir
brincidofovir
current
undergo
phase
iii
clinic
trial
adenoviru
cytomegaloviru
infect
drug
vitro
activ
ebolaviru
use
experiment
treatment
current
outbreak
repurpos
licens
drug
consid
treatment
evd
emerg
infecti
diseas
specif
antivir
treatment
tabl
ic
clomiphen
chloroquin
imatinib
tabl
experiment
postexposur
prophylaxistreat
lethal
ebolaviru
challeng
nonhuman
primat
peak
serum
level
human
therefor
unlik
use
clinic
toremifen
favipiravir
peak
serum
level
ic
drug
shown
improv
surviv
mous
model
toremifen
achiev
plasma
concentr
mm
high
dose
mgday
inhibitori
cell
cultur
ic
mm
vero
cell
howev
murin
model
util
high
dose
mgkg
initi
h
post
infect
achiev
surviv
moreov
prolong
qtc
chang
report
dose
mg
daili
thu
clinic
trial
consid
dosag
adjust
cardiac
electrolyt
monitor
favipiravir
also
appear
effect
mice
model
administ
patient
franc
although
efficaci
drug
human
uncertain
especi
nonhuman
primat
treatment
data
avail
may
consid
better
option
avail
benefitrisk
ratio
favor
sinc
fusion
viral
cellular
membran
endosom
play
import
role
viral
life
cycl
sever
studi
use
chemic
librari
screen
molecul
inhibit
process
fusion
step
use
strategi
molecul
inhibit
cathepsinl
mediat
cleavag
gp
bind
identifi
experi
postexposur
prophylaxi
human
mainli
come
laboratori
accid
scientist
us
armi
medic
research
institut
infecti
diseas
usamriid
suffer
needlestick
injuri
work
mouseadapt
variant
zair
ebolaviru
postexposur
prophylaxi
receiv
liveattenu
recombin
vesicular
stomat
viru
express
gp
zair
ebolaviru
h
accid
scientist
fever
h
receiv
vaccin
otherwis
remain
asymptomat
three
clinic
trial
conduct
first
trial
use
adenovirusbas
vaccin
express
gp
involv
subject
vaccin
group
subject
placebo
group
vaccin
group
divid
high
dose
low
dose
group
specif
antibodi
respons
develop
recipi
high
dose
vaccin
vaccin
welltoler
two
vaccin
recipi
complic
develop
antiphospholipid
antibodi
one
vaccin
recipi
develop
fever
c
second
trial
two
gp
zair
sudan
dna
vaccin
express
express
vector
produc
escherichia
coli
subject
vaccin
group
subject
placebo
group
specif
antibodi
respons
least
one
vaccin
antigen
develop
vaccin
recipi
second
vaccin
also
welltoler
vaccin
group
subject
develop
rais
creatin
phosphokinas
associ
vigor
exercis
subject
develop
herp
zoster
third
trial
studi
evalu
dna
vaccin
encod
wild
type
gp
antigen
zair
sudan
ebolaviru
produc
e
coli
ten
subject
enrol
seriou
advers
event
vaccin
elicit
specif
antibodi
gp
antigen
time
write
two
vaccin
undergo
phase
clinic
trial
vaccin
ebolaviru
consist
virusvector
adenoviru
type
human
parainfluenza
viru
type
vesicular
stomat
viru
viruslik
particl
np
gp
recombin
ebolaviru
test
anim
model
efficaci
vaccin
human
await
studi
current
evid
suggest
ebolaviru
transmit
via
contact
contamin
bodi
fluid
contamin
environ
therefor
practic
contact
precaut
appropri
person
protect
equip
ppe
utmost
import
handl
suspect
confirm
case
evd
healthcar
worker
prefer
work
pair
mutual
guard
break
infect
control
measur
requir
put
ppe
follow
sequenc
respir
water
repel
cap
hood
full
length
shoe
cover
boot
water
resist
gown
face
shield
long
nitril
glove
patient
hemorrhag
symptom
doubl
nitril
glove
worn
tabl
licens
drug
antivir
activ
ebolaviru
view
high
virul
mortal
patient
suspect
evd
isol
airborn
isol
room
develop
countri
although
allow
cohort
nurs
design
area
dedic
instrument
access
restrict
develop
countri
limit
isol
facil
degown
remain
critic
procedur
healthcar
worker
contamin
ppe
remov
first
long
nitrit
glove
water
resist
gown
full
length
shoe
cover
boot
face
shield
water
repel
cap
hood
final
respir
hand
hygien
alcoholbas
hand
rub
perform
step
degown
hand
visibl
soil
wash
soap
water
healthcar
worker
must
well
train
audit
proper
procedur
gown
degown
suspect
confirm
case
evd
die
healthcar
mortuari
worker
requir
wear
ppe
describ
dead
bodi
place
doubl
bag
leakproof
characterist
less
mm
thick
absorb
materi
put
bodi
place
first
bag
surfac
bodi
bag
wipe
ppm
sodium
hypochlorit
solut
bag
seal
label
indic
highlyinfecti
materi
categori
move
mortuari
immedi
view
funer
parlor
embalm
hygien
prepar
allow
dead
bodi
remov
bodi
bag
sent
cremat
soon
possibl
sinc
outbreak
first
report
march
situat
continu
deterior
consequ
catastroph
term
lost
live
also
sever
socioeconom
disrupt
high
risk
spread
countri
august
declar
evd
outbreak
west
africa
public
health
emerg
intern
concern
prepared
respons
plan
made
avail
health
author
world
aim
detect
first
import
case
earli
isol
order
prevent
local
transmiss
commun
healthcar
set
risk
assess
port
health
emerg
room
outpati
clinic
patient
fulfil
clinic
epidemiolog
criteria
evd
import
clinic
definit
patient
suffer
sudden
onset
fever
c
least
one
follow
sign
includ
inexplic
bleed
bloodi
diarrhea
bleed
gum
bleed
skin
eye
hematuria
alert
epidemiolog
definit
includ
close
contact
confirm
probabl
case
evd
resid
histori
travel
affect
area
countri
within
day
onset
symptom
healthcar
worker
work
volunt
medic
servic
nongovern
organ
direct
contact
patient
affect
area
countri
also
perform
medic
surveil
least
day
leav
affect
area
countri
requir
seek
medic
advic
promptli
symptom
fever
diarrhea
vomit
rash
bleed
medic
surveil
one
major
problem
current
outbreak
panic
associ
diseas
mani
patient
symptom
seek
medic
care
fear
contract
diseas
hospit
therefor
local
govern
health
author
focu
health
educ
give
clear
instruct
person
seek
earli
medic
attent
unaffect
area
africa
howev
commun
transmiss
ebolaviru
uncontrol
implement
home
quarantin
day
one
incub
period
consid
home
quarantin
measur
use
control
commun
spread
sar
beij
taiwan
singapor
toronto
howev
public
health
staff
expect
face
unpreced
challeng
implement
extens
quarantin
polici
dual
role
monitor
complianc
provid
support
daili
necess
peopl
quarantin
countri
next
affect
area
requir
implement
border
control
measur
screen
suspect
case
ebolaviru
although
measur
may
advers
affect
intern
travel
economi
may
worthwhil
implement
strict
measur
control
reemerg
infecti
diseas
high
mortal
psycholog
fear
time
manner
human
constantli
threat
infecti
diseas
emerg
infecti
diseas
especi
import
human
histori
signific
loss
popul
econom
disrupt
polit
instabl
yersinia
pesti
caus
black
death
europ
kill
onethird
popul
cholera
outbreak
major
earthquak
haiti
remind
us
seemingli
easytotreat
control
infect
caus
larg
outbreak
infrastructur
damag
sar
coronaviru
mer
coronaviru
avian
influenza
virus
caus
epidem
major
health
econom
effect
current
west
africa
evd
outbreak
unpreced
largest
evd
outbreak
local
transmiss
outsid
africa
one
major
differ
previou
outbreak
affect
crowd
major
citi
west
africa
infrastructur
heavili
damag
due
civil
war
rapid
spread
facilit
effici
persontoperson
transmiss
due
high
viral
load
blood
bodili
secret
contamin
environ
larg
amount
viru
particl
shed
bodi
fluid
make
viru
contagi
even
among
healthcar
worker
alreadi
equip
ppe
whole
genom
studi
show
current
west
africa
ebolaviru
strain
phylogenet
distinct
previou
outbreak
strain
current
ebolaviru
strain
higher
mutat
rate
previou
strain
howev
current
known
whether
strain
particularli
virul
transmiss
current
major
gap
understand
diseas
due
lack
systemat
epidemiolog
patholog
clinic
virolog
studi
taken
grant
develop
countri
exampl
pandem
epidem
caus
coronavirus
influenza
virus
mani
studi
conduct
quickli
within
month
outbreak
result
allow
earli
control
outbreak
implement
scientif
sound
clinic
manag
patient
coordin
effort
involv
virologist
clinician
epidemiologist
govern
intern
organ
necessari
prevent
evd
outbreak
becom
pandem
author
declar
conflict
interest
